1.26 billion! Minimally invasive to buy the United States medical equipment business

Pharmaceutical Network November 23 hearing Hong Kong media said that minimally invasive medical announced the acquisition of LivaNova PLC CRM business, has entered into a legally binding letter of intent with a preliminary consideration of 190 million US dollars (about 1.482 billion Hong Kong dollars) for working capital and other Routine adjustment.

According to Hong Kong's top financial news network reported on November 21, CRM business mainly in Europe, including the operation, including the design, manufacture, distribution of equipment monitoring the patient's heart conditions in order to identify arrhythmias and ventricular fibrillation and other heart abnormalities and current to prevent or treat the abnormal Happening.

Minimally Invasive Medical believes that the acquisition of CRM business from Liva Nova will allow the company's CRM-enabled companies to consolidate its leadership position in the Chinese market for cardiovascular intervention products and accelerate the pace of sales of CRM devices in the Chinese market. In addition, the acquisition is mainly in Europe The operation of CRM business can expand the company's operating scale in Europe and expand the institutional investors' rights and interests in the company.

According to U.S. GAAP accounts, the revenue of CRM business last year was approximately US $ 246 million (approximately HK $ 1,918 million). The vendor Liva Nova is incorporated in the United Kingdom and is listed on the NASDAQ Global Select Market.

Reference News Network - Reporters learned that minimally invasive medical is a high-end medical instruments Group, focused on the global R & D, manufacturing and sales of high-end medical device products.

Micro-invasive medical products have been listed on more than 200 products, covering cardiovascular interventional products, orthopedic medical equipment, aortic and peripheral vascular interventional products, electrophysiology medical devices, nerve interventional products, cardiac rhythm management products, diabetes and endocrine medical devices and surgical operations Ten areas.

Minimally Invasive Medical Products have now reached more than 5,000 worldwide hospital Covering major markets such as Asia Pacific, Europe and the Americas, and in 2016, minimally invasive medical services recorded approximately $ 390 million in revenue.

LivaNova's heart rhythm management business mainly consists of researching, manufacturing and marketing products for the diagnosis, treatment and management of arrhythmias and heart failure. Its main products include defibrillators, heart Resynchronization therapy devices and pacemakers have been implanted in more than a million cases worldwide in nearly 40 years.

The global potential market valuation of the heart rhythm management business is estimated to have reached about 10 billion U.S. dollars. "Dr. Wang Li, Chief Executive Officer of Cardiac Armed Services, said:" This acquisition will allow domestic pacemakers to finally stand up with world-class products from their followers The same starting line, but also will speed up its localization process.We will stand in a high starting point of international quality, better and faster for Chinese patients with more features and targeted refinement, personal treatment and management programs.

The deal for minimally invasive medical and LivaNova is expected to close in the second quarter of 2018.